Common and disorder-specific upregulation of the inflammatory markers TRAIL and CCL20 in depression and schizophrenia
© 2021. The Author(s)..
Schizophrenia (SZ) and major depressive disorder (MDD) are severe mental disorders, which have been associated with alterations of the peripheral inflammatory network. However, studies for both disorders have not been fully consistent and have focused on few canonical markers with high relevance to the innate immune system, while the role of the adaptive immune system is studied less. Furthermore, it is unclear to what extent inflammatory abnormalities are diagnosis-specific or transdiagnostic. The purpose of this study was to investigate 75 peripheral inflammatory markers including the acute phase protein high-sensitivity C-reactive protein (hsCRP) in patients with MDD (n = 37), SZ (n = 42) and healthy controls (HC) (n = 17), while considering possible confounders and correcting rigorously for multiple testing in group comparisons. We identified C-C chemokine ligand 20 (CCL20) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) as the inflammatory markers with significant group differences after controlling for multiple comparisons and adjusting for BMI, sex and smoking as confounders. TRAIL was elevated in both MDD and SZ compared to HC. CCL20 was specifically increased in SZ compared to MDD and HC. There were no significant group differences in hsCRP after correcting for multiple testing. Finally, we observed no significant correlations among CCL20, TRAIL and CRP. TRAIL is a transdiagnostic marker for SZ and MDD, with both markers being independent from CRP and body mass index (BMI). CCL20 may be a novel and specific biomarker of schizophrenia, but an influence of antipsychotic medication cannot be excluded. Identifying novel markers in mental disease bears the potential for future research towards novel treatment strategies by modifying inflammation-related processes.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
---|---|
Enthalten in: |
Scientific reports - 11(2021), 1 vom: 28. Sept., Seite 19204 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Klaus, Federica [VerfasserIn] |
---|
Links: |
---|
Themen: |
Biomarkers |
---|
Anmerkungen: |
Date Completed 27.12.2021 Date Revised 27.12.2021 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1038/s41598-021-98769-0 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM331257092 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM331257092 | ||
003 | DE-627 | ||
005 | 20231226203633.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1038/s41598-021-98769-0 |2 doi | |
028 | 5 | 2 | |a pubmed24n1104.xml |
035 | |a (DE-627)NLM331257092 | ||
035 | |a (NLM)34584171 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Klaus, Federica |e verfasserin |4 aut | |
245 | 1 | 0 | |a Common and disorder-specific upregulation of the inflammatory markers TRAIL and CCL20 in depression and schizophrenia |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 27.12.2021 | ||
500 | |a Date Revised 27.12.2021 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2021. The Author(s). | ||
520 | |a Schizophrenia (SZ) and major depressive disorder (MDD) are severe mental disorders, which have been associated with alterations of the peripheral inflammatory network. However, studies for both disorders have not been fully consistent and have focused on few canonical markers with high relevance to the innate immune system, while the role of the adaptive immune system is studied less. Furthermore, it is unclear to what extent inflammatory abnormalities are diagnosis-specific or transdiagnostic. The purpose of this study was to investigate 75 peripheral inflammatory markers including the acute phase protein high-sensitivity C-reactive protein (hsCRP) in patients with MDD (n = 37), SZ (n = 42) and healthy controls (HC) (n = 17), while considering possible confounders and correcting rigorously for multiple testing in group comparisons. We identified C-C chemokine ligand 20 (CCL20) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) as the inflammatory markers with significant group differences after controlling for multiple comparisons and adjusting for BMI, sex and smoking as confounders. TRAIL was elevated in both MDD and SZ compared to HC. CCL20 was specifically increased in SZ compared to MDD and HC. There were no significant group differences in hsCRP after correcting for multiple testing. Finally, we observed no significant correlations among CCL20, TRAIL and CRP. TRAIL is a transdiagnostic marker for SZ and MDD, with both markers being independent from CRP and body mass index (BMI). CCL20 may be a novel and specific biomarker of schizophrenia, but an influence of antipsychotic medication cannot be excluded. Identifying novel markers in mental disease bears the potential for future research towards novel treatment strategies by modifying inflammation-related processes | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Observational Study | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 7 | |a Biomarkers |2 NLM | |
650 | 7 | |a CCL20 protein, human |2 NLM | |
650 | 7 | |a Chemokine CCL20 |2 NLM | |
650 | 7 | |a TNF-Related Apoptosis-Inducing Ligand |2 NLM | |
650 | 7 | |a TNFSF10 protein, human |2 NLM | |
700 | 1 | |a Guetter, Karoline |e verfasserin |4 aut | |
700 | 1 | |a Schlegel, Rebecca |e verfasserin |4 aut | |
700 | 1 | |a Spiller, Tobias R |e verfasserin |4 aut | |
700 | 1 | |a Seifritz, Erich |e verfasserin |4 aut | |
700 | 1 | |a Cathomas, Flurin |e verfasserin |4 aut | |
700 | 1 | |a Kaiser, Stefan |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Scientific reports |d 2011 |g 11(2021), 1 vom: 28. Sept., Seite 19204 |w (DE-627)NLM215703936 |x 2045-2322 |7 nnns |
773 | 1 | 8 | |g volume:11 |g year:2021 |g number:1 |g day:28 |g month:09 |g pages:19204 |
856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41598-021-98769-0 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 11 |j 2021 |e 1 |b 28 |c 09 |h 19204 |